ReviewJournal of clinical and experimental hematopathology : JCEH2025
Pathobiological link between CD30 and abnormal lymphocytes in adult T-cell leukemia/lymphoma.
Review in Journal of clinical and experimental hematopathology : JCEH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult T-cell leukemia/lymphoma (ATLL) is a T-cell malignancy with poor prognosis caused by human T-cell leukemia virus type 1 (HTLV-1). ATLL is characterized by the emergence of abnormal lymphocytes, represented by the so called "flower cell". However, the mechanisms by which these cells contribute to tumorigenic processes associated with HTLV-1 infection are not well understood. Recent reports have suggested that CD30, tumor necrosis factor receptor superfamily 8 plays a role in the generation of these abnormal lymphocytes, providing insight into the involvement of CD30 in the tumorigenic process of HTLV-1-infected cells. Since CD30 can be targeted with brentuximab vedotin (BV), an anti-CD30 antibody linked with monomethyl auristatin E, a tubulin toxin, it is essential to gain a deeper understanding of the functions of CD30 in HTLV-1-infected cells in order to develop effective strategies for treating and preventing ATLL. This review describes the current understanding of how CD30 impacts the development of ATLL in cells infected with HTLV-1, with a specific emphasis on the connection between CD30 and the generation of abnormal lymphocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.